1 Solution

Rethink prenatal screening.
Think VeriSeq NIPT Solution.

View Video
 

In-Lab Screening Using NIPT

NIPT Has Never Been Simpler

2

Hours Hands-On Time

0

Hours on Amplification

1.5

Days faster than competing NIPTs*†

Lower failure rate

Revolutionizing Prenatal Screening with NIPT

It's time to change the way you think about prenatal screening using NIPT. The VeriSeq NIPT Solution is a simple, noninvasive prenatal testing (NIPT) IVD solution for your lab that is now available in certain European Union countries. With only 2 hours of hands-on time and no PCR or amplification step, screening with NIPT has never been simpler.

The automated and validated workflow includes CE-marked sample prep and assay software. One lab technician can load a sequencer and get accurate results the following day. Are you ready to revolutionize your workflow?

Watch how the VeriSeq NIPT Solution can take you from sample to results with an automated workflow.

View Video
NIPT automated workflow video graphic
VeriSeq NIPT Brochure

Learn more about the VeriSeq NIPT Solution—an easy, sample–to–result workflow. It's the only solution you need.

Read Brochure
VeriSeq NIPT Solution Data Sheet

Get information on the reagents, instruments, and CE-IVD marked library prep and analysis software for in-lab prenatal screening.

Read Data Sheet
NIPT Technology Guide

Learn more about NIPT and key considerations when selecting a technology for screening with NIPT.

Download Guide
Understanding the VeriSeq NIPT Solution Assay

Dive into the VeriSeq NIPT assay and learn how it works.

View Video

*Assumes 1 workshift per day
† Data on file. Illumina, Inc. 2016.
‡ Data on file. Illumina, Inc. 2018.

Intended Use

The VeriSeq NIPT Solution is an in vitro diagnostic test intended for use as a sequencing-based screening test for the detection of fetal aneuploidies from maternal peripheral whole blood samples in pregnant women of at least 10 weeks gestation. VeriSeq NIPT provides information regarding aneuploidy status for chromosomes: 21, 18, 13, X, and Y. This product must not be used as the sole basis for diagnosis or other pregnancy management decisions.

Limitations of the test

Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. False positive and false negative results do occur. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. A negative result does not eliminate the possibility that the pregnancy has a chromosomal or sub chromosomal abnormality. This test does not screen for polyploidy (eg, triploidy), birth defects such as open neural tube defects, single gene disorders, or other conditions, such as autism. There is a small possibility that the test results might not reflect the chromosomal status of the fetus, but may instead reflect chromosomal changes in the placenta (confined placental mosaicism, CPM) or the mother that may or may not have clinical significance.